Vividion acquires WRN inhibitor to enhance oncology pipeline
VVD-214 is a clinical-stage Werner helicase (WRN) inhibitor that targets cancers with high microsatellite instability (MSI), such as colorectal, endometrial, ovarian, and gastric cancers.
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma
FDA approves Bayer’s Nubeqa for advanced prostate cancer treatment
Takeda secures EC approval for Adcetris to treat Hodgkin lymphoma
Sanofi’s Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Agenus, Zydus enter $141m collaboration to advance BOT/BAL
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry